Literature DB >> 19777158

The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease.

Agnieszka Ciesielska1, I Joniec, I Kurkowska-Jastrzebska, A Cudna, A Przybyłkowski, A Członkowska, A Członkowski.   

Abstract

OBJECTIVE: The aim of the present study was to determine how aging and gender influence the response of astrocytes to 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP) intoxication.
MATERIALS AND METHODS: To asses the MPTP-induced astrocytes activation in nigro-striatal system, we measured the temporal changes in mRNA and protein expression of the specific astrocytic marker, glial fibrillary acidic protein (GFAP; by RT-PCR and Western blot), in the striatum of male and female C57BL/6 mice (2 and 12-month old) after 6 h and 1, 3, 7, 14 and 21 days post-intoxication.
RESULTS: We observed the increases of GFAP mRNA level post-MPTP intoxication in both young and aging males only at early time points, whereas in females (both ages) also at later time points. We noticed maximal increase of GFAP protein content on the 3rd day post-intoxication in young and aged males, whereas in females at the 7-daytime point.
CONCLUSIONS: The present results provide additional information of potential relevance to understand the mechanisms of gender and age-related difference in susceptibility of nigro-striatal system to MPTP insult.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19777158     DOI: 10.1007/s00011-009-0026-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  33 in total

Review 1.  Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.

Authors:  Bianca Marchetti; Pier Andrea Serra; Francesca L'Episcopo; Cataldo Tirolo; Salvo Caniglia; Nuccio Testa; Serena Cioni; Florinda Gennuso; Gaia Rocchitta; Maria Speranza Desole; Maria Clorinda Mazzarino; Egidio Miele; Maria Concetta Morale
Journal:  Ann N Y Acad Sci       Date:  2005-12       Impact factor: 5.691

Review 2.  Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease.

Authors:  Liang-Wei Chen; Kin-Lam Yung; Ying-Shing Chan
Journal:  Curr Drug Targets       Date:  2005-11       Impact factor: 3.465

3.  The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse.

Authors:  I Kurkowska-Jastrzebska; A Wrońska; M Kohutnicka; A Członkowski; A Członkowska
Journal:  Exp Neurol       Date:  1999-03       Impact factor: 5.330

4.  Astrocytic hypertrophy and altered GFAP degradation with age in subcortical white matter of the rhesus monkey.

Authors:  J A Sloane; W Hollander; D L Rosene; M B Moss; T Kemper; C R Abraham
Journal:  Brain Res       Date:  2000-04-17       Impact factor: 3.252

Review 5.  Gender, neuroendocrine-immune interactions and neuron-glial plasticity. Role of luteinizing hormone-releasing hormone (LHRH).

Authors:  B Marchetti; F Gallo; Z Farinella; C Tirolo; N Testa; S Caniglia; M C Morale
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

6.  Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.

Authors:  Tanuja Bordia; Sharon R Grady; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2007-04-04       Impact factor: 4.436

7.  Gonadal hormone regulation of glial fibrillary acidic protein immunoreactivity in the medial amygdala subnuclei across the estrous cycle and in castrated and treated female rats.

Authors:  Flávia G Martinez; Erica E S Hermel; Léder L Xavier; Giordano G Viola; João Riboldi; Alberto A Rasia-Filho; Matilde Achaval
Journal:  Brain Res       Date:  2006-07-13       Impact factor: 3.252

8.  GFAP Transgenic Mice

Authors: 
Journal:  Methods       Date:  1996-12       Impact factor: 3.608

9.  Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  Ilona Joniec; Agnieszka Ciesielska; Iwona Kurkowska-Jastrzebska; Adam Przybylkowski; Anna Czlonkowska; Andrzej Czlonkowski
Journal:  Brain Res       Date:  2009-01-18       Impact factor: 3.252

10.  The impact of gender and estrogen on striatal dopaminergic neurotoxicity.

Authors:  D B Miller; S F Ali; J P O'Callaghan; S C Laws
Journal:  Ann N Y Acad Sci       Date:  1998-05-30       Impact factor: 5.691

View more
  12 in total

1.  Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease.

Authors:  C Venkateshappa; G Harish; Rajeswara Babu Mythri; Anita Mahadevan; M M Srinivas Bharath; S K Shankar
Journal:  Neurochem Res       Date:  2011-10-05       Impact factor: 3.996

Review 2.  The neurotoxicity of environmental aluminum is still an issue.

Authors:  Stephen C Bondy
Journal:  Neurotoxicology       Date:  2010-05-27       Impact factor: 4.294

Review 3.  Function and therapeutic value of astrocytes in neurological diseases.

Authors:  Hong-Gyun Lee; Michael A Wheeler; Francisco J Quintana
Journal:  Nat Rev Drug Discov       Date:  2022-02-16       Impact factor: 112.288

4.  Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.

Authors:  Fabrine S M Tristão; Majid Amar; Ines Latrous; Elaine A Del-Bel; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-05-21       Impact factor: 3.911

Review 5.  Sex differences in Parkinson's disease.

Authors:  Glenda E Gillies; Ilse S Pienaar; Shiv Vohra; Zahi Qamhawi
Journal:  Front Neuroendocrinol       Date:  2014-03-04       Impact factor: 8.606

6.  Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease.

Authors:  Loubna Boukhzar; Abdallah Hamieh; Dorthe Cartier; Yannick Tanguy; Ifat Alsharif; Matthieu Castex; Arnaud Arabo; Sana El Hajji; Jean-Jacques Bonnet; Mohammed Errami; Anthony Falluel-Morel; Abdeslam Chagraoui; Isabelle Lihrmann; Youssef Anouar
Journal:  Antioxid Redox Signal       Date:  2016-03-16       Impact factor: 8.401

7.  Sex influences in neurological disorders: case studies and perspectives.

Authors:  Janine Austin Clayton
Journal:  Dialogues Clin Neurosci       Date:  2016-12       Impact factor: 5.986

8.  The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.

Authors:  Joanna Schwenkgrub; Malgorzata Zaremba; Ilona Joniec-Maciejak; Agnieszka Cudna; Dagmara Mirowska-Guzel; Iwona Kurkowska-Jastrzębska
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

9.  A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  H L Martin; R B Mounsey; K Sathe; S Mustafa; M C Nelson; R M Evans; P Teismann
Journal:  Neuroscience       Date:  2013-03-07       Impact factor: 3.708

10.  Salvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease models.

Authors:  Jie Zhou; Xiao-Dong Qu; Zhi-Yun Li; Qi Liu; Yi-Hui Ma; Jiao-Jiang He
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.